- Supported exchanges /
- ST /
- KAN.ST
Kancera AB (publ) (KAN ST) stock market data APIs
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Kancera AB (publ) Financial Data Overview
| 0.864 | |
| 1.342 | |
| - | |
| 1.28 | |
| 0.98 | |
| 0.8-6.7699 | |
| 131 M | |
| 121 M | |
| -592 000 | |
| -0.0913 | |
| 1.745 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Kancera AB (publ) Fundamental Data is available in our Financial Data APIs
- Net Revenue -592 000
- EBITDA -50 404 000
- Earnings Per Share -0.53
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Kancera AB (publ) Earnings via APIs
- Latest Release 2024-11-15
- EPS/Forecast NaN
Get Kancera AB (publ) End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
